Citations

Clear

1446 citation(s) found for "Howard, F".

Experimental Constriction of Inflow Tracts in the Heart: Analysis of Circulatory Failure
Boucek, Robert J. , Grindlay, John H., Burchell, Howard B.

Mayo Clinic

American Journal of Physiology-Legacy Content | December 25, 2017 | Volume: 169 | Issue: 2 | Pages: 442-452

10.1152/ajplegacy.1952.169.2.442 | PMID 14933611 Get It

Duration of QT Interval at Slow Ventricular Rates
Klakeg, Clayton H., Berry, Anna M., Burchell, Howard B.

Mayo Clinic

American Journal of Physiology-Legacy Content | December 21, 2017 | Volume: 179 | Issue: 1 | Pages: 159-164

10.1152/ajplegacy.1954.179.1.159 | PMID 13207406 Get It

Methylprednisolone acetate induces, and Δ7-dafachronic acid suppresses, Strongyloides stercoralis hyperinfection in NSG mice
Patton, John B., Bonne-Année, Sandra, Deckman, Jessica M., Hess, Jessica A., Torigian, April, Nolan, Thomas J. , Wang, Zhu , Kliewer, Steven A. , Durham, Amy C. , Lee, James J. , Eberhard, Mark L., Mangelsdorf, David J. , Lok, James B. , Abraham, David

Mayo Clinic

Proceedings of the National Academy of Sciences | December 4, 2017 | Volume: 115 | Issue: 1 | Pages: 204-209

10.1073/pnas.1712235114 | PMID 29203662 Get It

Significance The intestinal parasite Strongyloides stercoralis infects an estimated 100 million people. This nematode’s unique ability to autoinfect its host enables it to persist for decades undetected and to progress to a potentially fatal hyperinfection that often is induced by glucocorticoid treatment. We report a mouse model, involving the NSG strain, that recapitulates all forms of human strongyloidiasis. Even in severely immunocompromised NSG mice, glucocorticoid treatment was required for autoinfection, raising intriguing questions about the mechanism of glucocorticoid action. Notably, administering a nematode-derived steroid, Δ7-dafachronic acid, which acts through a receptor within S. stercoralis to regulate parasite development, significantly diminished autoinfection in glucocorticoid-treated NSG mice. This opens the possibility of new chemotherapy for hyperinfective strongyloidiasis, targeting the parasite’s own steroid hormone mechanisms.
Early Parental Abuse and Daily Assistance to Aging Parents With Disability: Associations With the Middle-Aged Adults’ Daily Well-being
Liu, Yin , Bangerter, Lauren R. , Almeida, David M. , Kong, Jooyoung , Zarit, Steven Howard

Mayo Clinic

The Journals of Gerontology: Series B | November 29, 2017 | Volume: 73 | Issue: 5 | Pages: e59-e68

10.1093/geronb/gbx173 | PMID 29325175 Get It

Microfluidic chest cavities reveal that transmural pressure controls the rate of lung development
Nelson, Celeste M. , Gleghorn, Jason P. , Pang, Mei-Fong, Jaslove, Jacob M. , Goodwin, Katharine , Varner, Victor D. , Miller, Erin , Radisky, Derek C. , Stone, Howard A.

Mayo Clinic

Development | November 28, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1242/dev.154823 | PMID 29084801 Get It

Mechanical forces are increasingly recognized to regulate morphogenesis, but how this is accomplished in the context of the multiple tissue types present within a developing organ remains unclear. Here we use bioengineered “microfluidic chest cavities” to precisely control the mechanical environment of the fetal lung. We show that transmural pressure controls airway branching morphogenesis, the frequency of airway smooth muscle contraction, and the rate of developmental maturation of the lungs, as assessed by transcriptional analyses. Timelapse imaging reveals that branching events are synchronized across distant locations within the lung, and are preceded by long-duration waves of airway smooth muscle contraction. Higher transmural pressure decreases the interval between systemic smooth muscle contractions and increases the rate of morphogenesis of the airway epithelium. These data reveal that the mechanical properties of the microenvironment instruct crosstalk between different tissues to control the development of the embryonic lung.
Longitudinal trajectories of subjective care stressors: the role of personal, dyadic, and family resources
Bangerter, Lauren R. , Liu, Yin , Zarit, Steven Howard

Mayo Clinic

Aging & Mental Health | November 24, 2017 | Volume: 23 | Issue: 2 | Pages: 255-262

10.1080/13607863.2017.1402292 | PMID 29171960 Get It

Effects of alteplase for acute stroke according to criteria defining the European Union and United States marketing authorizations: Individual-patient-data meta-analysis of randomized trials
Hacke, Werner , Lyden, Patrick D. , Emberson, Jonathan , Blackwell, Lisa, Albers, Gregory W. , Bluhmki, Erich , Brott, Thomas, Cohen, Geoffrey, Davis, Stephen M. , Grotta, James C. , Howard, George , Kaste, Markku , Koga, Masatoshi , Lansberg, Maarten G. , Lindley, Richard I. , Olivot, Jean‐Marc , Toni, Danilo , Wahlgren, Nils , Wardlaw, Joanna M. , Whiteley, William , Zoppo, Gregory del, Group, on behalf of the Stroke Thrombolysis Trialists’ Collaborators, Lindley, Richard I , Sandercock, Peter Ag , Wardlaw, Joanna Marguerite , Baigent, Colin , Cohen, Geoff, Donnan, Geoffrey A. , Kummer, Rüdiger von , Parsons, Mark W , Sandercock, Peter , Toyoda, Ḱazunori , Lees, Kennedy R. , Group, on behalf of the Stroke Thrombolysis Trialists’ Collaborators, Howard, George , Whiteley, William N , Grotta, James C

Mayo Clinic

International Journal of Stroke | November 24, 2017 | Volume: 13 | Issue: 2 | Pages: 175-189

10.1177/1747493017744464 | PMID 29171359 Get It

Background The recommended maximum age and time window for intravenous alteplase treatment of acute ischemic stroke differs between the Europe Union and United States. Aims We compared the effects of alteplase in cohorts defined by the current Europe Union or United States marketing approval labels, and by hypothetical revisions of the labels that would remove the Europe Union upper age limit or extend the United States treatment time window to 4.5 h. Methods We assessed outcomes in an individual-patient-data meta-analysis of eight randomized trials of intravenous alteplase (0.9 mg/kg) versus control for acute ischemic stroke. Outcomes included: excellent outcome (modified Rankin score 0–1) at 3–6 months, the distribution of modified Rankin score, symptomatic intracerebral hemorrhage, and 90-day mortality. Results Alteplase increased the odds of modified Rankin score 0–1 among 2449/6136 (40%) patients who met the current European Union label and 3491 (57%) patients who met the age-revised label (odds ratio 1.42, 95% CI 1.21−1.68 and 1.43, 1.23−1.65, respectively), but not in those outside the age-revised label (1.06, 0.90−1.26). By 90 days, there was no increased mortality in the current and age-revised cohorts (hazard ratios 0.98, 95% CI 0.76−1.25 and 1.01, 0.86–1.19, respectively) but mortality remained higher outside the age-revised label (1.19, 0.99–1.42). Similarly, alteplase increased the odds of modified Rankin score 0-1 among 1174/6136 (19%) patients who met the current US approval and 3326 (54%) who met a 4.5-h revised approval (odds ratio 1.55, 1.19−2.01 and 1.37, 1.17−1.59, respectively), but not for those outside the 4.5-h revised approval (1.14, 0.97−1.34). By 90 days, no increased mortality remained for the current and 4.5-h revised label cohorts (hazard ratios 0.99, 0.77−1.26 and 1.02, 0.87–1.20, respectively) but mortality remained higher outside the 4.5-h revised approval (1.17, 0.98–1.41). Conclusions An age-revised European Union label or 4.5-h-revised United States label would each increase the number of patients deriving net benefit from alteplase by 90 days after acute ischemic stroke, without excess mortality.
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update
Amstutz, Ursula , Henricks, Linda M. , Offer, Steven M. , Barbarino, Julia M., Schellens, Jan H.M. , Swen, Jesse J. , McLeod, Howard L. , Caudle, Kelly E. , Diasio, Robert B. , Schwab, Matthias , Lau‐Min, Kelsey S. , Klein, Teri E. , Offer, Steven M , Schwab, Matthias

Mayo Clinic

Clinical Pharmacology & Therapeutics | November 20, 2017 | Volume: 103 | Issue: 2 | Pages: 210-216

10.1002/cpt.911 | PMID 29152729 Get It

The purpose of this guideline is to provide information for the interpretation of clinical dihydropyrimidine dehydrogenase ( DPYD ) genotype tests so that the results can be used to guide dosing of fluoropyrimidines (5‐fluorouracil and capecitabine). Detailed guidelines for the use of fluoropyrimidines, their clinical pharmacology, as well as analyses of cost‐effectiveness are beyond the scope of this document. The Clinical Pharmacogenetics Implementation Consortium (CPIC ® ) guidelines consider the situation of patients for which genotype data are already available (updates available at https://cpicpgx.org/guidelines/guideline‐for‐fluoropyrimidines‐and‐dpyd/ ).
A Case of KCNQ2 -Associated Movement Disorder Triggered by Fever
Dhamija, Radhika , Goodkin, Howard P. , Bailey, Russell C., Chambers, Chelsea , Brenton, J. Nicholas , Brenton, J Nicholas , Dhamija, Radhika

Mayo Clinic

Journal of Child Neurology | November 12, 2017 | Volume: 32 | Issue: 14 | Pages: 1123-1124

10.1177/0883073817736702 | PMID 29129156 Get It

The differential diagnosis of fever-induced movement disorders in childhood is broad. Whole exome sequencing has yielded new insights into those cases with a suspected genetic basis. We report the case of an 8-year-old boy with a history of neonatal seizures who presented with near-continuous hyperkinetic movements of his limbs during a febrile illness. Initial diagnostic testing did not explain his abnormalities; however, given the suspicion for a channelopathy, whole exome sequencing was performed and it demonstrated a de novo pathogenic heterozygous variant in KCNQ2. There is an expanding phenotypic spectrum of heterozygous alterations in KCNQ2; however, this report provides the first description of a pathogenic KCNQ2 variant fever-induced hyperkinetic movement disorder in childhood. We also review the literature of cases previously published with the same pathogenic variant.